Država: Europska Unija
Jezik: engleski
Izvor: EMA (European Medicines Agency)
sevelamer hydrochloride
Genzyme Europe BV
V03AE02
sevelamer hydrochloride
All other therapeutic products
Hyperphosphatemia; Renal Dialysis
Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.,
Revision: 4
Withdrawn
2015-02-25
16 B. PACKAGE LEAFLET Medicinal product no longer authorised 17 PACKAGE LEAFLET: INFORMATION FOR THE USER TASERMITY 800 MG FILM-COATED TABLETS sevelamer hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tasermity is and what it is used for 2. What you need to know before you take Tasermity 3. How to take Tasermity 4. Possible side effects 5. How to store Tasermity 6. Contents of the pack and other information 1. WHAT TASERMITY IS AND WHAT IT IS USED FOR Tasermity contains sevelamer as the active ingredient. It binds phosphate from food in the digestive tract and so reduces serum phosphate levels in the blood. Tasermity is used to control the levels of phosphate in the blood of adult kidney failure patients on haemodialysis or peritoneal dialysis treatment. Adult patients whose kidneys have failed and who are undergoing haemodialysis or peritoneal dialysis are not able to control the level of serum phosphate in their blood. The amount of phosphate then rises (your doctor will call this hyperphosphataemia). Increased levels of serum phosphorus can lead to hard deposits in your body called calcification. These deposits can stiffen your blood vessels and make it harder for blood to be pumped around the body. Increased serum phosphorus can also lead to itchy skin, red eyes, bone pain and fractures. Tasermity may be used with other medicines which include calcium or vitamin D supplements to control the development of renal bone disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TASERMITY DO NOT Pročitajte cijeli dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Tasermity 800 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 800 mg sevelamer hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) The off-white, oval tablets are imprinted with “SH800” on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D 3 or one of its analogues to control the development of renal bone disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Starting dose_ The recommended starting dose of sevelamer hydrochloride is 2.4 g or 4.8 g per day based on clinical needs and serum phosphorus level. Sevelamer hydrochloride must be taken three times per day with meals. Serum phosphate level in patients not on phosphate binders Starting dose of Sevelamer hydrochloride 800 mg tablets 1.76 – 2.42 mmol/L (5.5-7.5 mg/dl) 1 tablet, 3 times per day > 2.42 mmol/L (>7.5 mg/dl) 2 tablets, 3 times per day For patients previously on phosphate binders, Sevelamer hydrochloride should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses. _Titration and maintenance _ Serum phosphate levels should be closely monitored and the dose of sevelamer hydrochloride titrated by 0.8 g three times per day (2.4 g/day) increments with the goal of lowering serum phosphate to 1.76 mmol/L (5.5 mg/dl) or less. Serum phosphate should be tested every two to three weeks until a stable serum phosphate level is reached and on a regular basis thereafter. The dose range may vary between 1 and 5 tablets of 800 mg per meal. The average actual daily dose used in the chronic Pročitajte cijeli dokument